Woolsey Pharma

Coming – December 1

ALS Patients Can't Wait for a Cure

Date and Time

December 1

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

An Executive Briefing with Woolsey Pharmaceuticals

For people living with amyotrophic lateral sclerosis (ALS), time is measured in more than months and years. It’s measured in the ability to walk, speak, breathe, and live independently. With most patients dying within two to five years of diagnosis, there is an urgent need for treatments that can slow the disease’s devastating progression.

Woolsey Pharmaceuticals is developing BRAVYL, a novel oral formulation of fasudil designed to protect motor neurons and preserve physical function in people living with ALS.

Rather than starting with an entirely new molecule, Woolsey is building on more than 30 years of clinical experience with fasudil, a drug used intravenously in Japan. Its approach targets ROCK, a signaling pathway implicated in motor neuron injury, survival, and repair.

Early clinical evidence provides a foundation for further development:
  • Independent randomized clinical evidence: A European Phase 2a study involving 118 ALS patients found evidence of preserved motor-unit function with intravenous fasudil.
  • Encouraging biomarker findings: Woolsey’s 62-patient Phase 2a study found 20% lower levels of neurofilament light chain, a marker of neuronal injury, among patients receiving BRAVYL at 180 mg daily compared with matched external controls after six months.
  • Potential functional benefits: Exploratory comparisons suggested slower declines in physical function, muscle strength, and respiratory capacity.
  • Regulatory recognition: BRAVYL has received FDA Fast Track and Orphan Drug designations.

Woolsey is preparing to initiate a randomized Phase 2b trial involving approximately 125 patients, with a projected clinical readout approximately 18 months after the trial begins.

Led by experienced pharmaceutical executives Sven Jacobson and David Geliebter, Woolsey is advancing an approach that could complement existing ALS therapies and potentially help patients maintain their independence longer.

Join our Executive Briefing to hear directly from Woolsey’s leadership about the science behind BRAVYL, the clinical evidence to date, and the company’s plans for its next stage of development.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.